Boyu Capital, established in 2010, is a Hong Kong-based private equity firm with an additional office in Beijing. It specializes in investing in China, with a focus on healthcare services, pharmaceuticals and biotechnology, life science, and oncology sectors.
Ouro Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic, immune-mediated illnesses. It specializes in integrating scientific knowledge and clinical trial experience to develop innovative, cell-depleting therapies. The company's core technology involves T cell engager antibodies that target and eliminate specific pathogenic cells, aiming to provide extended remissions for patients without the need for continuous immunosuppression.
Timberlyne Therapeutics
Series A in 2025
Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across multiple autoimmune diseases.
Seek Pet
Private Equity Round in 2024
Seek Pet Foods is an original equipment manufacturer and original design manufacturer specializing in the development and production of pet food and related products. The company utilizes innovative technologies, including American micropowder puffing and fresh meat emulsification, to create nutritious pet food. By incorporating locally sourced, ecologically sustainable fresh chicken and duck meat along with other natural ingredients, Seek Pet Foods aims to provide customers with healthy options for their pets.
Positive Sequence Biology
Series A in 2024
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
Shuaike Pet Food Products
Venture Round in 2024
Shuaike is a company specializing in pet supplies and food. The brand is derived from the English "seek", adheres to the brand management philosophy of "only natural fresh meat", and aims to make the best natural and healthy food for pets all over the world. American micro powder puffing technology and fresh meat emulsification technology, combined with local fresh chicken and duck meat, natural food, organic vegetables, fruits, and other nutrients to extract natural fresh meat pet food, now export dog food and cat food Shuikesaijia Natural cat and dog food.
Xiaohongshu
Secondary Market in 2024
Xiaohongshu, founded in 2013 and based in Shanghai, China, is a lifestyle sharing platform that allows users to share experiences through text, images, and videos. Initially aimed at assisting overseas travelers with shopping, it has transformed into a vibrant community focused on various lifestyle areas, including cosmetics, fashion, food, travel, entertainment, reading, fitness, and childcare. The platform serves as a social e-commerce space where users can post their favorite products, share shopping experiences, and discover global merchandise, particularly in luxury and beauty sectors. By fostering user-generated content, Xiaohongshu encourages a collaborative environment for lifestyle enthusiasts to exchange insights and recommendations.
Global Data Solutions
Post in 2024
Global Data Solutions Limited is a data center operator based in Shanghai, China, with additional facilities in Beijing, Chengdu, Shenzhen, Kunshan, and Guangzhou. Founded in 2000 by William Wei Huang, the company specializes in designing, building, and managing data centers, providing services such as colocation, managed hosting, and managed cloud solutions. It offers information technology outsourcing services, including business continuity and disaster recovery, which encompass planning, design, implementation, and operation. The company primarily serves clients in the Internet and banking sectors, as well as a range of industries including finance, energy, manufacturing, aviation, telecommunications, and large corporations, both domestic and multinational. Global Data Solutions aims to deliver high-quality infrastructure and support to enhance operational efficiency and reliability for its diverse customer base across the Asia-Pacific region.
Chunqing Technology
Series A in 2024
Chunqing Technology is a company that create new generation of electric vehicles powered by alcohol and hydrogen. Chunqing Technology creates, manufactures, and distributes alcohol and hydrogen energy for the next generation of electric automobiles.
Tai Hydrogen Energy
Seed Round in 2024
Tai Hydrogen Energy is an energy solutions provider that focuses on the core products and application of clean energy based on green electricity and green hydrogen. It is a subsidiary of Chint Group.
Jingkong Energy
Series D in 2023
Jingkong Energy is an energy system research and development platform. They offer services for the development of smart power supply, electric power and energy storage, and fuel cell fields.
Doujin Culture
Seed Round in 2023
Doujin Culture is a cross-border e-commerce company that specializes in supporting brands seeking to expand their reach globally. It operates an e-commerce platform tailored for international users, facilitating the export of domestic products to global markets.
Quasar-Med
Acquisition in 2023
Quasar specializes in the manufacture of products for the medical device market, including catheters, electronics, and disposables. From initial design to mass production, Quasar’s integrative approach ensures superior outcomes, top quality, and cost-efficiency for clients. Founded in Hong Kong in 1988 by Boaz Amitai, the company was created to serve as a connection between its European, American, and Israeli customers and Chinese electronics manufacturers.
Farizon
Series A in 2023
Farizon Auto, established in 2014 by Geely's New Energy Commercial Vehicles Group, is a pioneering brand in China's new energy commercial vehicle sector. Over the years, Farizon has developed a range of urban and highway commercial vehicles, focusing on pure electric and range-extended electric power systems, as well as liquid hydrogen and methanol power technologies. Its product offerings include heavy trucks, light trucks, small and mini trucks, light commercial vehicles, and buses, catering to various commercial applications. Farizon operates the largest new energy commercial vehicle research institute in China, supported by over 2,000 research engineers globally. Aiming to lead the green commercial revolution, Farizon integrates intelligent transportation technology with a green energy supply network, providing comprehensive services throughout the vehicle life cycle. The company's vision includes contributing to zero-carbon land transport in China through innovative solutions in new energy commercial vehicles.
Tianbing Technology
Series C in 2023
Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meet cost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system.
Animoca Brands
Convertible Note in 2022
Animoca Brands, established in 2019 and headquartered in the Cayman Islands, is a venture capital firm focused on the technology sector. It invests in and supports creators who leverage web3 and blockchain technologies to drive digital property rights to gamers and internet users through non-fungible tokens (NFTs). The company develops and markets a portfolio of mobile applications, games, and educational products, utilizing gamification and blockchain to ensure transparency, security, and innovative business models.
Frontera Therapeutics
Series B in 2022
Frontera Therapeutics is a company specializing in adeno-associated virus (AAV) gene therapy, focused on developing and commercializing cost-effective recombinant virus-based therapies. The company aims to create a scalable platform that produces high-quality, affordable rAAV therapies for a range of genetic disorders, including ophthalmic, liver, metabolic, and neuromuscular diseases. Frontera Therapeutics has a diverse product pipeline that encompasses multiple therapeutic areas, with various candidates at different stages of development. By prioritizing affordability and quality, the company seeks to enhance the lives of patients through innovative genetic therapies.
Evat Master
Series A in 2022
Evat Master is a software-as-a-service (SaaS) platform that focuses on delivering independent European VAT declarations specifically for cross-border e-commerce businesses. The platform streamlines the tax reporting process, enabling users to complete all required tax procedures online. By offering a user-friendly interface, Evat Master simplifies the complexities of VAT compliance, making it easier for businesses engaged in international trade to manage their tax obligations effectively.
Shuaike Pet Food Products
Private Equity Round in 2022
Shuaike is a company specializing in pet supplies and food. The brand is derived from the English "seek", adheres to the brand management philosophy of "only natural fresh meat", and aims to make the best natural and healthy food for pets all over the world. American micro powder puffing technology and fresh meat emulsification technology, combined with local fresh chicken and duck meat, natural food, organic vegetables, fruits, and other nutrients to extract natural fresh meat pet food, now export dog food and cat food Shuikesaijia Natural cat and dog food.
MoreSec
Series D in 2022
Hangzhou MoreSec Technology Co., Ltd. is a company based in Hangzhou, China, specializing in internet security software. It focuses on integrating threat intelligence and artificial intelligence technologies into enterprise security systems. MoreSec aims to provide comprehensive security solutions tailored for the cloud computing and Internet of Things (IoT) environments, addressing the evolving needs of businesses in safeguarding their digital assets.
ArriVent Biopharma
Series A in 2022
ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company is committed to addressing unmet medical needs in oncology by leveraging its team's extensive drug development experience. ArriVent aims to maximize the potential of its lead candidate, furmonertinib, while advancing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. With an initial emphasis on solid tumors, ArriVent seeks to bring differentiated medicines from development through to commercialization, ultimately improving patient outcomes in cancer treatment.
Recurrent.ai
Venture Round in 2021
Recurrent.ai is a Chinese company that specializes in AI-enabled corporate services aimed at enhancing sales efficiency. The company offers a comprehensive sales dialogue analysis system that converts voice interactions into text, facilitating in-depth analysis of sales calls and customer service conversations. By leveraging machine learning, Recurrent.ai helps businesses generate detailed big data dialogue analysis reports and maintain customer portrait records. These capabilities enable companies to optimize their sales processes, reduce labor costs, and improve sales conversion rates, ultimately supporting more informed decision-making.
Jinke
Post in 2021
Jinke Property Group Co., Ltd. is a prominent real estate development company based in Chongqing, China, established in 1994. The company focuses on developing residential, industrial, and commercial properties while also providing property management services for various types of buildings, including residential complexes, commercial centers, office structures, and hotels. In addition to its core real estate activities, Jinke is involved in generating wind power and operating hotels. The company offers a range of services such as asset management, industrial investment, and wealth management, along with specialized services in landscape design and architectural decoration. It aims to integrate eco-friendly practices into its projects, emphasizing the development of green residential areas and eco-cities. Jinke has cultivated a strong organizational culture that contributes to its ongoing growth and operational effectiveness.
Vision Medicals Technology
Series D in 2021
Vision Medicals specializes in pathogenic gene diagnostic services, aiming to enhance medical treatment precision for infections. The company utilizes advanced technologies such as high-throughput sequencing-based pathogen metagenomics and CRISPR for rapid diagnostics, significantly improving the ability to detect clinical pathogens and reducing reporting times. Vision Medicals has developed proprietary nucleic acid enrichment technology to identify pathogenic micronucleic acids in clinical samples. By leveraging an extensive database of pathogen detection, the company has established a comprehensive pathogen macro, supported by a genomics intelligent analysis and reporting system. Through its focus on research and development, Vision Medicals seeks to lead the medical diagnostic industry with innovative detection technology platforms that enhance the efficiency and accuracy of medical diagnoses.
J&T Express
Private Equity Round in 2021
J&T Express is a logistics service provider founded in 2015 and headquartered in Jakarta, Indonesia. The company specializes in express delivery and courier services, primarily supporting the growth of the e-commerce sector. J&T Express operates in 13 countries across Southeast Asia, positioning itself as a leader in the region's express delivery market. By utilizing automated sorting warehouses in Indonesia and Singapore, J&T Express enhances operational efficiency and speed. The company caters to major e-commerce platforms, facilitating their expansion into new markets and contributing to the rapid development of its partners.
Positive Sequence Biology
Series A in 2021
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
Edge Medical Robotics
Series C in 2021
Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.
Zeekr
Seed Round in 2021
Zeekr develops and manufactures premium electric vehicles and automobiles. It specializes in the fields of electronics, automotive and electric vehicles.
MediTrust Health
Series C in 2021
MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.
Pulse
Series C in 2021
Pulse is a health care service provider that assess coronary physiology and biomechanics through innovative techniques.
Pulse Medical Technology
Series C in 2021
Pulse Medical Technology develops innovative technology for the diagnosis and optimal treatment of pan-vascular diseases.
PolarisIC
Seed Round in 2021
Polarisic specializes in the development of advanced measurement and imaging chip products, primarily utilizing single-photon avalanche diode (SPAD) technology. The company offers two main product lines: direct photon time-of-flight (dToF) measurement chips and low-light imaging chips. The dToF chips are designed for applications such as Unmanned Aerial Vehicle (UAV) height determination, obstacle avoidance, navigation for automated guided vehicles (AGVs), and smart perception in the Internet of Things (IoT). The low-light imaging chips feature high sensitivity and pixel digitization capabilities, making them suitable for night vision systems, security monitoring, smart industrial measurement, and enhanced smartphone photography. Polarisic is recognized for its technological innovations in dToF detection, high-speed digital processing, detection algorithm fusion, and system integration.
ArriVent Biopharma
Series A in 2021
ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company is committed to addressing unmet medical needs in oncology by leveraging its team's extensive drug development experience. ArriVent aims to maximize the potential of its lead candidate, furmonertinib, while advancing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. With an initial emphasis on solid tumors, ArriVent seeks to bring differentiated medicines from development through to commercialization, ultimately improving patient outcomes in cancer treatment.
Soul APP
Series D in 2021
Launched in 2016, Soul App is now one of the leading social networking applications in China. With a robust user base among Chinese Gen Z, Soul was designed to empower self-value expression and foster genuine relationships based on interest graphs and AI algorithms. Soul aspires to build a virtual social playground for its users to socialize, connect and maintain relationships free from the geographic and social constraints. Soul is the first social networking platform in China that requires all users to interact through avatars, and has a unique business model driven by the integration of intensive user interactions and an engaging community. Soul distinguishes itself from other peers with focus on virtual identities, open-ended relationships based on interest graphs, extensive user generated content (UGC), decentralized content distribution and its proprietary technologies. Nowadays, Soul pioneers in embracing the AI technologies in the social networking industry to meet the evolving social demand from the younger generation. In 2020, Soul kicked off its AIGC technology R&D. In 2023, Soul launched a proprietary large language model (LLM), Soul X, and has seamlessly embedded AI capabilities across use cases on its platform, which epitomizes Soul's product philosophy of the “Synergic Model-application Interplay”.
J&T Express
Private Equity Round in 2021
J&T Express is a logistics service provider founded in 2015 and headquartered in Jakarta, Indonesia. The company specializes in express delivery and courier services, primarily supporting the growth of the e-commerce sector. J&T Express operates in 13 countries across Southeast Asia, positioning itself as a leader in the region's express delivery market. By utilizing automated sorting warehouses in Indonesia and Singapore, J&T Express enhances operational efficiency and speed. The company caters to major e-commerce platforms, facilitating their expansion into new markets and contributing to the rapid development of its partners.
Klook
Series E in 2021
Klook is a global online platform facilitating the booking of travel experiences, services, and accommodations. It offers a wide array of activities such as tours, theme park tickets, cultural experiences, and adventure activities across numerous destinations worldwide. Additionally, Klook provides essential travel services like public transport passes, airport transfers, car rentals, SIM cards/eSIMs, and dining reservations to cater to various aspects of travel planning.
Lalamove
Series F in 2021
Lalamove, originally known as EasyVan, was established in Hong Kong in December 2013 to address the demand for efficient van hire services. The company operates in 21 markets across Asia and Latin America, connecting over 7 million customers with a network of more than 700,000 driver-partners. Lalamove's on-demand logistics platform facilitates instant matching between customers and drivers, enabling same-day deliveries with an impressive average fulfillment time of just 55 minutes. The platform offers van-hailing and courier services, allowing customers to track their deliveries in real time and rate their drivers. By optimizing routes and fleets, Lalamove enhances the earning potential for drivers while providing reliable and swift delivery solutions for businesses and individuals alike.
SciNeuro
Series A in 2020
SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.
D3 Bio
Series A in 2020
D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines within the fields of oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methods targeting new disease pathways and delivery routes, with the ultimate goal of providing patients with novel and effective therapy options.
Yuanfudao
Series G in 2020
Yuanfudao, founded in 2012, is the largest online live course platform in China, catering to primary and secondary school students. With over 1 million paying users, it provides a comprehensive curriculum that includes subjects such as English, Mathematical Olympiad, and various all-subject courses for secondary education. The platform features live online tutoring conducted by nationally recognized teachers, allowing students to receive quality education from home. By utilizing big data analysis, Yuanfudao enables students to identify their learning weaknesses and engage in targeted learning, thus enhancing their educational outcomes. The combination of its extensive course offerings and a large pool of qualified educators benefits hundreds of thousands of students across the country.
Antengene
Series C in 2020
Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.
Yuanfudao
Series G in 2020
Yuanfudao, founded in 2012, is the largest online live course platform in China, catering to primary and secondary school students. With over 1 million paying users, it provides a comprehensive curriculum that includes subjects such as English, Mathematical Olympiad, and various all-subject courses for secondary education. The platform features live online tutoring conducted by nationally recognized teachers, allowing students to receive quality education from home. By utilizing big data analysis, Yuanfudao enables students to identify their learning weaknesses and engage in targeted learning, thus enhancing their educational outcomes. The combination of its extensive course offerings and a large pool of qualified educators benefits hundreds of thousands of students across the country.
Perfect Diary
Venture Round in 2020
Perfect Diary is an e-commerce-based cosmetic brand. The company is committed to exploring the trends in international cosmetics and the frontiers of fashion to provide easy-to-use cosmetics products for young Asian women.Perfect Diary is professional in branding and online traffic management. By launching co-branded cosmetic products with KOLs, idols and even some famous organizations like the British Museum
PDD Holdings
Post in 2020
PDD Holdings (Nasdaq: PDD) is a multinational commerce group that owns and operates a portfolio of businesses. PDD Holdings aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD Holdings has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses.
Kuaishou Technology
Series F in 2019
Kuaishou Technology, founded in 2011 and based in Beijing, China, operates an online video and photo sharing application known as Kuaishou. The platform enables users to broadcast their daily activities and engage with a global audience through short videos, photos, and live streams. Kuaishou aims to enhance individual happiness by leveraging big data and artificial intelligence technology, promoting equal opportunities through its algorithms and ethical values. The app empowers everyday individuals in China to share their experiences and connect with fans worldwide. Additionally, Kuaishou has an international counterpart, Kwai, which offers similar features tailored for users outside of China. With an average of 275.9 million daily active users, Kuaishou generates revenue by selling virtual items, online marketing, and earning commissions from e-commerce transactions on its platform.
Chengjia Apartment
Series A in 2019
Chengjia Apartment is a rental start-up that provides different product choices for apartments, hotels, and homestays. Chengjia Apartment extends the business scope to weekly rent, monthly rent, and long-term rent. The company creates a high-quality living environment with ingenuity, take care of every guest with hotel-style service, and creates a warm, comfortable, and temperature-friendly home. Chengjia Apartment is jointly established by China Living Hotel Group and IDG Capital. It has laid out nearly 100 properties in first-tier cities nationwide, with more than 10,000 houses and services. It was founded on 2015 and is headquartered in Shanghai, China.
Waterdrop
Series C in 2019
Waterdrop is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. It's the largest independent third-party insurance platform in China in terms of life and health insurance first year premiums, distributed in 2020, according to iResearch. Through Waterdrop Insurance Marketplace and Medical Crowdfunding platforms, Waterdrop have built a massive social network of protection and support for people, raising awareness of insurance and ultimately providing insurance and healthcare service to consumers in China. It had listed on the New York Stock Exchange under the symbol “WDH” in May 2021.
Yimidida
Series D in 2019
Yimidida is an online logistics network based in Shanghai, China, that specializes in crowd-sourced delivery services, particularly to rural towns. Founded in 2015, the platform facilitates the delivery of products of various sizes to villages across China. Yimidida's offerings include payment collection, transport insurance, return receipts, and delivery tracking, all aimed at enhancing the efficiency of dispatch and truck deployment. This comprehensive logistics solution enables customers to receive their orders promptly, regardless of their location.
Antengene
Series B in 2019
Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.
NetEase Cloud Music
Series B in 2018
NetEase Cloud Music, established in 2013 and based in Hangzhou, China, specializes in online music streaming services through its mobile application. The platform enables users to access a wide variety of music and offers additional features, such as music discovery and social networking capabilities. As a subsidiary of NetEase, Inc., NetEase Cloud Music has grown to become a significant player in the Chinese music streaming market, catering to the evolving preferences of its audience while developing applications for smartphones to enhance user experience.
LianLian
Venture Round in 2018
Lianlian Yintong Electronic Payment Co., Ltd, commonly known as Lianlian Pay, was established in 2003 and has grown to become the fourth largest non-banking third-party payment service provider in China, with a registered capital of RMB325 million. The company specializes in offering payment, clearing, and value-added mobile payment services, boasting over 60 payment licenses across various countries and regions. Lianlian Pay facilitates cross-border payments for approximately 100 sites linked to nearly 50 cross-border e-commerce platforms, extending its services to more than 100 countries. With a commitment to providing convenient, safe, and efficient payment solutions, Lianlian has accumulated a client base of over 1.1 million cross-border e-commerce stores and has established a significant presence in the global payment landscape. Additionally, it became one of the inaugural partners in the China (Hangzhou) Cross-border E-commerce Comprehensive Pilot Area, which was the first national-level pilot zone approved by the Chinese government.
LianLian
Venture Round in 2018
Lianlian Yintong Electronic Payment Co., Ltd, commonly known as Lianlian Pay, was established in 2003 and has grown to become the fourth largest non-banking third-party payment service provider in China, with a registered capital of RMB325 million. The company specializes in offering payment, clearing, and value-added mobile payment services, boasting over 60 payment licenses across various countries and regions. Lianlian Pay facilitates cross-border payments for approximately 100 sites linked to nearly 50 cross-border e-commerce platforms, extending its services to more than 100 countries. With a commitment to providing convenient, safe, and efficient payment solutions, Lianlian has accumulated a client base of over 1.1 million cross-border e-commerce stores and has established a significant presence in the global payment landscape. Additionally, it became one of the inaugural partners in the China (Hangzhou) Cross-border E-commerce Comprehensive Pilot Area, which was the first national-level pilot zone approved by the Chinese government.
Klook
Series D in 2018
Klook is a global online platform facilitating the booking of travel experiences, services, and accommodations. It offers a wide array of activities such as tours, theme park tickets, cultural experiences, and adventure activities across numerous destinations worldwide. Additionally, Klook provides essential travel services like public transport passes, airport transfers, car rentals, SIM cards/eSIMs, and dining reservations to cater to various aspects of travel planning.
Curon Biopharma
Series A in 2018
Curon Biopharma is focused on developing drugs for immuno-oncology therapies. The company offers a range of innovative cancer immunotherapeutic agents aimed at overcoming the limitations of existing cancer treatment approaches. By providing advanced immunotherapies, Curon Biopharma enables physicians to enhance treatment options for their patients battling cancer.
MEGVII
Series D in 2018
Incorporated in 2011, Megvii is committed to make greatest value for customers and the whole society with extraordinary technology. Megvii is an Artificial Intelligence company specialized in providing enterprises and developers with intelligent solutions and data services, and is dedicated to the mission of “Create machines that can see and think”. Based on its original deep learning system Brain++, Megvii seeks to build AI Engine, a core fundamental technology powering various AI application. It is leveraging on recognition, control, optimization and other algorithms to connect individuals, objects and scenarios, building a product platform of IoT OS. It is connecting standardized hardware like sensors, robots and personal devices with AI+IoT (AIoT), thus commercializing three application-oriented IoT brains on a large scale, namely, city brain, supply chain brain, and personal life brain. Megvii is building an operation system for the era of AIoT. Megvii is an AIoT solutions expert.
Trax
Series D in 2018
Trax Technology Solutions Pte Ltd. specializes in providing in-store execution solutions, focusing on image recognition technology that transforms mobile images into actionable insights for the retail sector. Founded in 2010 and headquartered in Singapore, Trax serves tier-one manufacturers and channel partners both locally and internationally. Its innovative platform enables sales representatives to access detailed information about product availability, shelf share, pricing, and compliance swiftly through mobile devices. This technology enhances operational efficiency and effectiveness for consumer goods companies. Trax has established itself as a leader in computer vision solutions for the consumer packaged goods industry, partnering with various innovators in IoT technologies to capture retail realities. The company's clientele includes major global brands, and it operates offices across multiple regions, including APAC, Europe, the Middle East, North America, and South America.
Brii Biosciences
Venture Round in 2018
Brii Biosciences Limited is a biotechnology company focused on the research, development, and commercialization of innovative medicines for chronic and infectious diseases, including hepatitis B virus (HBV), human immunodeficiency virus (HIV), and multi-drug resistant infections. Founded in 2018, the company is headquartered in Durham, North Carolina, with additional offices in Shanghai, Beijing, and San Francisco. Brii Biosciences aims to enhance healthcare outcomes for patients in China by leveraging advanced technology and data. The company has established strategic partnerships with organizations such as AliHealth and Vir to further its mission. With a robust pipeline consisting of over 10 product candidates, Brii Biosciences is dedicated to addressing significant public health challenges both in China and globally, focusing on delivering better treatments and cures for life-threatening diseases.
China Chengxin Credit
Series A in 2018
China Chengxin Credit Co., Ltd. is a credit rating agency based in Beijing, China, with additional offices in Wuhan and Shanghai. Founded in 2005, the company offers a wide range of services related to credit information. These services include personal credit solutions such as credit reports, credit scores, credit monitoring, anti-fraud measures, and customized offerings. For corporate clients, the company provides credit reports, e-commerce certification, and pre-loan surveys for microfinance. China Chengxin Credit is also involved in social credit construction, assisting regional governments, industry platforms, enterprises, and institutions in developing and implementing comprehensive credit systems. Additionally, the company offers market research consulting, which encompasses industry reports and management consulting, further enhancing its value proposition in the fintech sector.
CStone Pharmaceuticals
Series B in 2018
CStone Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing and commercializing innovative immuno-oncology and molecularly targeted drugs aimed at addressing significant unmet medical needs in cancer treatment. Founded in 2015 and headquartered in Shanghai, China, the company has established a robust product pipeline that includes several late-stage clinical candidates, such as CS1001, a monoclonal antibody targeting programmed death ligand 1, and CS1003, which targets programmed death receptor. Other notable products include ivosidenib, avapritinib, and pralsetinib, along with a variety of additional investigational drugs for solid tumors and other cancer indications. CStone engages in strategic collaborations, including a licensing agreement with Numab Therapeutics for a tri-specific antibody and a clinical partnership with Bayer HealthCare to assess the efficacy of CS1001 in combination therapies. The company aims to enhance treatment options for cancer patients both in China and globally through its dedicated research and development efforts.
Viela Bio
Series A in 2018
Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, designed for conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. In addition to inebilizumab, Viela Bio is developing VIB4920, aimed at preventing kidney transplant rejection and treating Sjögren's syndrome, and VIB7734, which targets cutaneous lupus erythematosus. The company has formed a strategic partnership with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, Viela Bio is committed to addressing critical pathways underlying autoimmune diseases to improve patient outcomes.
Berry Oncology
Series A in 2018
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
LifeMine Therapeutics
Series A in 2017
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.
iQIYI
Series G in 2017
iQIYI, Inc. is a prominent online entertainment platform in China, offering a wide range of services including internet video streaming, online gaming, live broadcasting, online literature, and e-commerce. Established in 2009 and headquartered in Beijing, the company operates under the iQIYI brand and has developed a comprehensive library of licensed and self-produced content across various genres such as movies, TV dramas, and animations. iQIYI generates revenue primarily through subscription services, boasting around 100 million paying subscribers and 500 million monthly active users. Additionally, the platform monetizes user-generated content through advertising, while also engaging in e-commerce via the iQIYI Mall, which specializes in entertainment-related merchandise. The company has diversified its offerings to include a live broadcasting service and a social media platform focused on entertainment. iQIYI faces competition from other streaming services such as Tencent Video and Alibaba's Youku, positioning itself as a leader in the rapidly evolving digital media landscape in China.
CStone Pharmaceuticals
Series A in 2016
CStone Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing and commercializing innovative immuno-oncology and molecularly targeted drugs aimed at addressing significant unmet medical needs in cancer treatment. Founded in 2015 and headquartered in Shanghai, China, the company has established a robust product pipeline that includes several late-stage clinical candidates, such as CS1001, a monoclonal antibody targeting programmed death ligand 1, and CS1003, which targets programmed death receptor. Other notable products include ivosidenib, avapritinib, and pralsetinib, along with a variety of additional investigational drugs for solid tumors and other cancer indications. CStone engages in strategic collaborations, including a licensing agreement with Numab Therapeutics for a tri-specific antibody and a clinical partnership with Bayer HealthCare to assess the efficacy of CS1001 in combination therapies. The company aims to enhance treatment options for cancer patients both in China and globally through its dedicated research and development efforts.
COFCO
Post in 2014
COFCO is a leading supplier of agricultural products and services based in Beijing, China. The company operates across various sectors within the agricultural and food industry, focusing on the trade, processing, and distribution of commodities such as grain, edible oils, sugar, and cotton. COFCO plays a crucial role in connecting domestic markets with international suppliers, serving as a key channel for the import and export of bulk agricultural products like wheat, corn, rice, and sugar. The company is committed to utilizing renewable natural resources to provide healthy and nutritious food while enhancing living standards and social prosperity. In addition to its core activities, COFCO is involved in various sectors, including real estate, hospitality, non-grain bio-energy, packaging, and finance, thereby diversifying its business portfolio and contributing to economic growth.
LY.com
Series C in 2014
LY.com allows users to search for places of interest at the local and city levels. LY.com pinpoints the right spots within a few clicks. Every place of interest comes with user reviews. If users are satisfied with the reviews, they can purchase tickets directly on the site. The company's goal is to become the leading service provider of leisure travel, making it easier for customers to enjoy travelling.
Berry Genomics
Series B in 2013
Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.
Alibaba Group
Private Equity Round in 2012
Alibaba Group is the largest online and mobile commerce company globally, primarily known for its extensive e-commerce platforms that connect buyers and sellers. It operates notable marketplaces in China, including Taobao, which focuses on consumer-to-consumer transactions, and Tmall, which caters to business-to-consumer interactions. The company's core business lies in its China commerce retail division, which is a significant source of cash flow. In addition to retail and wholesale transactions, Alibaba also generates revenue from various sectors, including international commerce, local consumer services, cloud computing, digital media and entertainment, and logistics through its Cainiao network. Alibaba's diverse portfolio positions it as a key player across multiple industries, including retail, logistics, and technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.